Optegra opens first London eye hospital

Article

Optegra announced the launch of its first eye Hospital in London this week.

Optegra announced the launch of its first eye Hospital in London this week.

The firm's sixth hospital consists of three consulting rooms, six diagnostic rooms, a treatment room and two operating theatres. It is equipped with high technology diagnostic and surgical equipment.

Optegra has hospitals located in Birmingham, Solent, Surrey, Yorkshire and Manchester. The company also runs several outreach clinics through partnerships with GPs and other ophthalmic professionals.

Managing Director of Optergra, Gareth Steer, commented, "Optegra’s vision is to become the most trusted provider of ophthalmology services, by working together with leading consultant ophthalmologists and providing the best facilities and highly trained staff, to deliver the best clinical outcomes and exceptional patient experience. We are pleased to announce the launch of our new hospital in London and we are delighted to bring the five star patient care, so closely associated with Optegra, to an even wider group of patients."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.